Company / Depreciation & Amortization
NovaBay Pharmaceuticals, Inc. Depreciation & Amortization History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$40.0K
FY2024
5-year range
$40.0K / $120.0K
FY2020-FY2024
Trend
-21.6%
vs FY2023
Sector context
#159 of 162
Health Care
What the data says
Among 162 Health Care companies, NovaBay Pharmaceuticals, Inc. is in the top 2% for depreciation & amortization. Depreciation & Amortization has fluctuated over the past 10 years, ranging from $40,000 in FY2024 to $266,000 in FY2018.
Based on SEC 10-K filings.
$40,000 in FY2024 with a 5-year CAGR of -9.3%.
Improved from $120,000 to $40,000 over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -12.2%
- 5-Year CAGR
- -9.3%
- 10-Year CAGR
- -
Sector benchmark
-100.0% below sector average
Key checks
Key Insights
- 5-year CAGR of -9.3%, indicating a declining trend.
- In FY2024, depreciation & amortization decreased 21.6% year-over-year.
- Ranks #159 out of 162 companies in the Health Care sector.
- Peak depreciation & amortization was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $40.0K | -21.6% |
| FY2023 | $51.0K | -57.5% |
| FY2022 | $120.0K | +103.4% |
| FY2021 | $59.0K | +15.7% |
| FY2020 | $51.0K | -21.5% |
| FY2019 | $65.0K | -75.6% |
| FY2018 | $266.0K | +180.0% |
| FY2017 | $95.0K | -16.7% |
| FY2016 | $114.0K | -30.5% |
| FY2015 | $164.0K | -29.3% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026